Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Puma Biotechnology (PBYI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,055,057
  • Shares Outstanding, K 38,135
  • Annual Sales, $ 27,690 K
  • Annual Income, $ -291,960 K
  • 36-Month Beta 0.61
  • Price/Sales 5.19
  • Price/Cash Flow N/A
  • Price/Book 22.53

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.92
  • Number of Estimates 3
  • High Estimate -0.87
  • Low Estimate -0.96
  • Prior Year -1.71
  • Growth Rate Est. (year over year) +46.20%

Price Performance

See More
Period Period Low Period High Performance
1-Month
23.65 +13.83%
on 01/22/19
28.42 -5.28%
on 02/05/19
+1.70 (+6.74%)
since 01/18/19
3-Month
19.46 +38.34%
on 12/24/18
28.42 -5.28%
on 02/05/19
+3.84 (+16.64%)
since 11/19/18
52-Week
17.60 +52.95%
on 11/02/18
83.15 -67.62%
on 03/09/18
-40.13 (-59.85%)
since 02/16/18

Most Recent Stories

More News
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on February 14, 2019 the Compensation Committee of Puma's Board of Directors approved the grant of inducement...

PBYI : 26.92 (-2.71%)
5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings

Let us take a look at five favorable stocks, poised to beat estimates this earnings season.

PBYI : 26.92 (-2.71%)
LLY : 122.13 (-0.29%)
ACAD : 22.98 (-1.16%)
PCRX : 39.94 (-1.82%)
REPH : 8.68 (+0.12%)
EPZM : 12.18 (-5.51%)
BMY : 51.36 (-0.60%)
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST onThursday, February 28, 2019 following release of its fourth...

PBYI : 26.92 (-2.71%)
Puma Biotechnolo Down 40.0% Since SmarTrend Downtrend Call (PBYI)

SmarTrend identified a Downtrend for Puma Biotechnolo (NASDAQ:PBYI) on October 10th, 2018 at $42.84. In approximately 4 months, Puma Biotechnolo has returned 39.96% as of today's recent price of $25.72....

PBYI : 26.92 (-2.71%)
Detailed Research: Economic Perspectives on Delta Air Lines, Duke Energy, Fiserv, The Chefs' Warehouse, Maxim Integrated Products, and Puma Biotechnology -- What Drives Growth in Today's Competitive Landscape

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Delta Air Lines, Inc. (NYSE:DAL),...

FISV : 85.62 (-0.19%)
PBYI : 26.92 (-2.71%)
CHEF : 34.34 (+0.94%)
DUK : 87.94 (+0.49%)
MXIM : 55.52 (-0.59%)
DAL : 51.82 (+1.45%)
Downtrend Call Working As Puma Biotechnolo Stock Falls 41.1% (PBYI)

SmarTrend identified a Downtrend for Puma Biotechnolo (NASDAQ:PBYI) on October 10th, 2018 at $42.84. In approximately 3 months, Puma Biotechnolo has returned 41.11% as of today's recent price of $25.23....

PBYI : 26.92 (-2.71%)
Puma Biotech (PBYI) Down More Than 40% in 90 Days: Here's Why

Puma Biotech's (PBYI) only marketed drug, Nerlynx, is suffering low sales due to higher patient discontinuations.

PBYI : 26.92 (-2.71%)
LLY : 122.13 (-0.29%)
NVS : 89.97 (+0.10%)
RHHBY : 34.3500 (+0.97%)
Puma Biotechnology and Knight Therapeutics Enter into Exclusive License Agreement to Commercialize NERLYNX(R) (neratinib) in Canada

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that it has entered into an exclusive License Agreement with Knight Therapeutics Inc. (TSX: GUD) that grants...

GUD.TO : 7.66 (unch)
PBYI : 26.92 (-2.71%)
Knight Therapeutics Runs with Exclusive Canadian License to Puma's NERLYNX(R)

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a Canadian specialty pharmaceutical company focused on acquiring, in-licensing, selling and marketing innovative prescription and over-the-counter pharmaceutical...

GUD.TO : 7.66 (unch)
PBYI : 26.92 (-2.71%)
KHTRF : 5.7751 (-0.21%)
Athenex Completes Enrollment Target for Breast Cancer Study

Athenex (ATNX) has completed target enrollment in the Oraxol phase III study in metastatic breast cancer on schedule.

ATNX : 12.83 (+1.50%)
PBYI : 26.92 (-2.71%)
RHHBY : 34.3500 (+0.97%)
PFE : 42.60 (+0.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators are in flux.

See More Share

Trade PBYI with:

Business Summary

Puma Biotechnology, Inc. is a biopharmaceutical company focused on the acquisition, in-licensing, development and commercialization of novel therapeutics for the treatment of cancer. Its products under development include PB272 (oral neratinib) for the treatment of patients with human epidermal growth...

See More

Key Turning Points

2nd Resistance Point 28.14
1st Resistance Point 27.91
Last Price 26.92
1st Support Level 27.25
2nd Support Level 26.82

See More

52-Week High 83.15
Fibonacci 61.8% 58.11
Fibonacci 50% 50.38
Fibonacci 38.2% 42.64
Last Price 26.92
52-Week Low 17.60

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar